The partners will collaborate on clinical studies aimed at driving health plan coverage for molecular diagnostic products.
The company announced positive coverage decisions from Palmetto GBA, 14 BCBS plans, and Aetna.
The company touted the recent spate of positive payor coverage decisions it has seen for its ConfirmMDx and SelectMDx prostate cancer tests.
The positive insurance coverage decision for ConfirmMDx is one of several the company has received in recent months.
CareFirst covers more than 3 million patients in Maryland, Washington DC, and Virginia, and is one several payors to recently issue a coverage decision for Vermillion.
The insurer will cover Metamark's urology specialized diagnostics throughout the state.
The colon cancer screening test is now covered in-network by the insurance company in Indiana, Ohio, Kentucky, Missouri, and Wisconsin.
Sequenom has secured in-network status with seven state Anthem BCBS plans to provide NIPT to both high- and average-risk pregnancies.
Exact Sciences' CEO recently discussed the added coverage on a call with analysts to discuss Exact's Q4 earnings.
The company alleges that the insurer has illegally and improperly refused to pay more than $410,000 for its colorectal cancer screening test Cologuard.
While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.
Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.
In Nature this week: paternal age associated with de novo mutations in children, and more.
Nature News writes that researchers are still wrangling over the role of the p-value.